Mersana Therapeutics Presents Positive Phase 1 Data for Cancer Drug Emi-Le at ASCO 2025

Mersana Therapeutics Inc. (NASDAQ:MRSN) is one of the best penny stocks under $1 to buy now. Earlier in June, Mersana Therapeutics presented additional positive interim Phase 1 clinical data for emiltatug ledadotin (Emi-Le; XMT-1660) at the American Society of Clinical Oncology/ASCO 2025 Annual Meeting in Chicago, Illinois. Emi-Le is the company’s B7-H4-directed Dolasynthen ADC.

The presentation focused on data from Emi-Le’s Phase 1 dose escalation and backfill cohorts, with a data cut-off of March 8, 2025. These cohorts included patients with triple-negative breast cancer/TNBC, hormone-receptor-positive and human epidermal growth factor receptor 2-negative breast cancer, ovarian cancer, endometrial cancer, and adenoid cystic carcinoma type 1 (ACC-1).

Mersana Therapeutics Presents Positive Phase 1 Data for Cancer Drug Emi-Le at ASCO 2025

A close-up of a hand holding a vial of biopharmaceutical drugs ready to be administered.

The safety and tolerability profile of Emi-Le, as of March 8, data cut-off, was consistent with initial data reported in January this year, with no new safety signals observed. Mersana Therapeutics is focusing its initial expansion work on patients with TNBC who have been previously treated with a topoisomerase-1 inhibitor ADC, recognizing this as a population with high unmet need.

Mersana Therapeutics Inc. (NASDAQ:MRSN) is a clinical-stage biopharmaceutical company that develops antibody-drug conjugates/ADC for cancer patients with unmet needs.

While we acknowledge the potential of MRSN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MRSN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.